ALX Oncology Holdings (ALXO)
(Delayed Data from NSDQ)
$1.95 USD
-0.04 (-2.01%)
Updated Sep 24, 2024 04:00 PM ET
After-Market: $1.92 -0.03 (-1.54%) 5:14 PM ET
3-Hold of 5 3
D Value C Growth C Momentum D VGM
Price, Consensus and EPS Surprise
ALXO 1.95 -0.04(-2.01%)
Will ALXO be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for ALXO based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALXO
uniQure (QURE) Soars on New Huntington's Disease Study Data
IDEAYA (IDYA) Up on Upbeat Phase II Bladder & Lung Cancer Data
ALXO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Adicet (ACET) Up as Kidney Cancer Drug Gets FDA's Fast Track Tag
Dianthus (DNTH) Gains 18% in the Past Month: Here's Why
Roche (RHHBY) Receives FDA Nod for Vabysmo Prefilled Syringe
Other News for ALXO
Wall Street Breakfast: The Week Ahead
Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers
ALX Oncology's Evorpacept Gains Momentum With FDA Fast Track Designations
ALX Oncology to Present at the 2024 Cantor Fitzgerald Global Healthcare Conference
ALX Oncology Announces First Patients Dosed with Evorpacept and Sarclisa As Part of Randomized Phase 1/2 UMBRELLA Study with Sanofi